On Monday, SK revealed that it will spend $260 million to construct its fifth production site in its home country, this one ...

Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. | ...

With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ...

Moderna has suffered its second PMCPA rebuke in quick succession. Days after ruling Moderna had brought discredit on the ...

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...

Otsuka is once again on the PMCPA’s naughty list as the U.K. drug marketing regulatory body has for the second time this year ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

Vaccine maker CSL Seqirus has lined up yet another contract with the U.S. | With a $121.4 million award from the U.S.

In the latest of several recent mpox vaccine supply deals, Bavarian Nordic plans to provide 1 million doses of its shot, ...